KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2025)

Amneal Pharmaceuticals has reported Other Operating Expenses over the past 9 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $4.8 million for Q4 2025, down 94.94% from a year ago — trailing twelve months through Dec 2025 was $5.2 million (up 231.86% YoY), and the annual figure for FY2025 was $5.2 million, up 463.44%.
  • Other Operating Expenses for Q4 2025 was $4.8 million at Amneal Pharmaceuticals, up from $390000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for AMRX hit a ceiling of $95.8 million in Q4 2024 and a floor of -$94.4 million in Q1 2024.
  • Median Other Operating Expenses over the past 5 years was $436000.0 (2023), compared with a mean of $445066.7.
  • Peak annual rise in Other Operating Expenses hit 15384.55% in 2021, while the deepest fall reached 31566.67% in 2021.
  • Amneal Pharmaceuticals' Other Operating Expenses stood at $18.8 million in 2021, then crashed by 89.04% to $2.1 million in 2022, then crashed by 242.62% to -$2.9 million in 2023, then skyrocketed by 3361.74% to $95.8 million in 2024, then tumbled by 94.94% to $4.8 million in 2025.
  • The last three reported values for Other Operating Expenses were $4.8 million (Q4 2025), $390000.0 (Q2 2025), and $95.8 million (Q4 2024) per Business Quant data.